Navigating the trade-offs of multiple myeloma maintenance therapy

Multiple myeloma remission maintenance therapy has quietly become one of the most consequential advances in modern oncology. It’s the primary reason the five-year survival rate for people with myeloma has nearly doubled over the past 30 years.

For decades, multiple myeloma was managed as a terminal diagnosis. Today, it’s increasingly treated as a chronic condition, and maintenance therapy is central to that transformation. After induction chemotherapy and, for eligible patients, an autologous stem cell transplant, the cancer may be in remission, but residual disease often lingers at levels too small to detect. Maintenance therapy steps in here, using lower-dose agents, most commonly lenalidomide (Revlimid), to suppress that residual activity and keep the M-spike, a protein marker of myeloma activity, from climbing back.

It helps to think of treatment in two distinct phases. The acute phase, induction and transplant, is an intensive sprint designed to achieve the deepest possible response. Maintenance is the marathon that follows, lower intensity but potentially running for years. This is also where the distinction between continuous therapy (ongoing treatment with no defined stop date) and fixed-duration therapy (a set number of cycles) becomes clinically meaningful, since the approach your care team recommends will shape your daily life and long-term health in ways the acute phase simply doesn’t.

The long-term physical reality. Managing cumulative side effects

Understanding multiple myeloma maintenance therapy’s long-term side effects is essential, because what you experience in year three can look very different from what you faced in the first few months.

Chronic neutropenia is among the ongoing risks that patients and care teams monitor during multiple myeloma maintenance therapy, and your medical team can discuss whether this is a particular concern for your treatment plan. Unlike the acute drops you may have seen during induction, neutropenia on maintenance tends to settle into a persistent, low-grade state that quietly raises your infection risk over time. Your care team will monitor your blood counts regularly, and dose adjustments are common, sometimes expected, when counts dip too low.

Then there’s what patients often describe as “persistent fatigue,” a dull, persistent tiredness that doesn’t always lift with rest. This differs from the exhaustion of active chemotherapy. Many patients find it shapes daily decisions in ways they didn’t fully anticipate. Energy budgeting for work, social events, and exercise becomes a quiet constant.

Gastrointestinal issues deserve special attention. Diarrhea is a known side effect of long-term lenalidomide use that can be significant enough to affect quality of life in multiple myeloma patients on maintenance therapy. In practice, bile acid sequestrants like Colestid can offer meaningful relief, a management option worth raising with your care team if GI disruption is affecting your quality of life. If you’re taking lenalidomide (whether branded as Revlimid or as a generic), it’s important to be aware of its potential side effects, which can range from common ones like nausea and fatigue to more serious effects like blood clots or liver problems.

Finally, high-dose chemotherapy with stem cell transplantation can cause genetic mutations and carries a risk of secondary cancers, though this risk is considered acceptable given the treatment benefits for multiple myeloma patients. Not every patient carries the same risk profile, and that’s where your genetics are a critical part of the conversation.

Risk-adapted strategies. Why your genetics dictate your protocol

Not every multiple myeloma diagnosis carries the same risk profile, and your maintenance protocol should reflect that. Genetic markers found in myeloma cells are among the most important factors in determining which maintenance approach your care team will recommend.

For most patients classified as standard risk, studies consistently show improved progression-free survival with lenalidomide maintenance compared to observation alone. This approach often involves years of daily or cyclical dosing.

High-risk disease requires a different approach. Chromosomal abnormalities like 17p deletion or the t(4,14) translocation can blunt lenalidomide’s effectiveness on its own. For these patients, bortezomib (Velcade) is frequently added or preferred because proteasome inhibitors can help overcome the poor prognostic impact of high-risk genetics.

As maintenance protocols become increasingly tailored to genetics, a related question is starting to emerge for some patients. Can a strong enough treatment response ever justify stopping therapy altogether? That’s where the concept of minimal residual disease testing becomes critical.

Can you ever stop maintenance?

The biggest question on most patients’ minds is whether they’ll ever get to stop. Minimal residual disease, or MRD, measures how deep a remission truly is, detecting cancer cells at a sensitivity of one myeloma cell per million. It’s reshaping how oncologists think about maintenance duration.

MRD-negative status and maintenance duration are increasingly intertwined in clinical trial design. MRD-negative status is emerging as the critical marker for guiding future personalized decisions about how long treatment should continue. Trials like the MASTER trial have used sustained MRD-negativity as a basis for “drug holidays,” allowing select patients to pause therapy under strict monitoring protocols. The conversation has shifted from the older fixed two-year courses versus indefinite treatment debate; now it centers on biology rather than time.

However, this progress comes with an important caveat. What works inside a rigorously monitored clinical trial doesn’t automatically translate to stopping therapy on your own. Discontinuing maintenance without either enrollment in a structured trial or direct supervision from your care team carries real relapse risk. Talk openly with your care team about whether MRD testing is appropriate for you and what your results might mean for your personalized care plan. That conversation is worth having, and it leads naturally into another layer of complexity that shapes long-term treatment decisions. The financial and logistical burden of staying the course.

Navigating financial toxicity and logistical hurdles

Long-term maintenance therapy in multiple myeloma carries a cost that goes well beyond side effects. For many patients, the financial and logistical weight can be as demanding as the treatment itself.

Specialty drug co-pays can quietly become one of the heaviest burdens of ongoing care. For patients on Revlimid, annual co-pay costs can reach thousands of dollars. Medicare patients may face co-pays in the $11,000 or higher range per year depending on their Part D plan, while commercially insured patients with co-pay assistance may have lower out-of-pocket costs. That figure compounds month after month across years of treatment. Several organizations, including Blood Cancer United’s Co-Pay Assistance Program and the Patient Advocate Foundation CO-PAY RELIEF program, offer co-pay assistance to help patients with the cost of specialty drugs. Asking your care team to connect you with a financial navigator is a reasonable, practical first step.

Logistical demands add another layer of fatigue. Monthly blood draws, routine oncology visits, and REMS program requirements (mandatory for lenalidomide dispensing) mean that maintenance is never truly passive. Over time, this rhythm of appointments can wear on patients emotionally and physically, a pattern real patient accounts consistently describe as treatment fatigue. It’s a predictable response to sustained effort.

The bottom line. What you need to know

Maintenance therapy is the single most important driver of long-term survival in multiple myeloma today, and understanding the trade-offs puts you in a stronger position to work with your care team.

Here’s what the evidence and clinical practice make clear:

• Lenalidomide is the current standard. Lenalidomide is currently the only myeloma treatment approved by the FDA for maintenance therapy after autologous stem cell transplant, with clinical trials showing improved progression-free and overall survival compared to placebo. For high-risk cytogenetics, combination therapy approaches are generally recommended.
• Side effect management is non-negotiable. Managing diarrhea long term, along with fatigue, is something your care team can actively support. Dose adjustments, dietary changes, and targeted interventions can protect your quality of life without compromising efficacy.
• MRD testing is reshaping the conversation. As covered earlier, minimal residual disease status is the most promising tool for determining whether maintenance can eventually be tapered or stopped safely, though that decision still requires rigorous, individualized assessment.
• Your personalized care plan evolves. What’s right at month six may not be right at year three. Individualized reassessment, including options to reduce doses, modify schedules, or stop treatment based on side effects and quality of life, may help sustain both response and wellbeing in multiple myeloma maintenance therapy, and should be discussed carefully with your doctor.

You are an active partner in shaping your multiple myeloma treatment plan. Patients who ask informed questions, track their own data, and advocate for adjustments when something isn’t working tend to get more responsive, personalized care. Your care team can only act on what they know, and you’re often the most important source of that information.

Download the Outcomes4Me app to connect with other people living with multiple myeloma. You don’t have to make sense of this alone. we’re here to help you navigate every step with clarity and confidence.

Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.